Ming Yin

5.2k total citations · 1 hit paper
80 papers, 3.1k citations indexed

About

Ming Yin is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ming Yin has authored 80 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 31 papers in Oncology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ming Yin's work include Bladder and Urothelial Cancer Treatments (16 papers), Renal cell carcinoma treatment (12 papers) and DNA Repair Mechanisms (11 papers). Ming Yin is often cited by papers focused on Bladder and Urothelial Cancer Treatments (16 papers), Renal cell carcinoma treatment (12 papers) and DNA Repair Mechanisms (11 papers). Ming Yin collaborates with scholars based in United States, China and Italy. Ming Yin's co-authors include Qingyi Wei, Darryl C. Zeldin, Samuel J. Arbes, Richard D. Cohn, Joseph J. Drabick, Li‐E Wang, Katarina Kulhánková, Peter S. Thorne, Monika Joshi and Zhongxing Liao and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Ming Yin

76 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis

2016 314 citations Ming Yin, Monika Joshi et al. The Oncologist profile →

Peers

Countries citing papers authored by Ming Yin

Since Specialization

Citations

This map shows the geographic impact of Ming Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Yin more than expected).

Fields of papers citing papers by Ming Yin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Yin. The network helps show where Ming Yin may publish in the future.

Co-authorship network of co-authors of Ming Yin

This figure shows the co-authorship network connecting the top 25 collaborators of Ming Yin. A scholar is included among the top collaborators of Ming Yin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming Yin. Ming Yin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Does Manual Acupuncture Improve Gastroesophageal Reflux Disease Symptoms? A Trial Sequential Meta-Analysis 2025 ·Complementary Medicine Research ·Jinjin Yin, Ming Yin, (unknown), Shumin Qin	0
2	A novel m7G-related miRNA prognostic signature for predicting clinical outcome and immune microenvironment in colon cancer 2024 ·Journal of Cancer ·(unknown), (unknown), Ming Yin, Peng Lei, (unknown)	1
3	Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low‐molecular‐weight heparin 2020 ·Cancer ·Sandip H. Patel, (unknown), Tzu‐Fei Wang, (unknown), Edmund Folefac, Menglin Xu, Yuanquan Yang, (unknown), Claire F. Verschraegen, Steven K. Clinton, Ming Yin	16
4	156P High TLR3 expression predicts improved survival in patients with clear cell renal cell carcinoma 2020 ·Annals of Oncology ·(unknown), (unknown), Paweł Kaliński, Claire F. Verschraegen, Steven K. Clinton, Yuanquan Yang, Amir Mortazavi, Paul Monk, Edmund Folefac, Ming Yin, (unknown), Ying Yang	0
5	Low-Dose Enzalutamide in Late-Elderly Patients (≥ 75 Years Old) Presenting With Metastatic Castration-Resistant Prostate Cancer 2020 ·Clinical Genitourinary Cancer ·Vincent Vinh‐Hung, (unknown), Clarisse Joachim, (unknown), Moustapha Dramé, (unknown), Edmund Folefac, Nam P. Nguyen, Claire F. Verschraegen, Ming Yin	17
6	ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2−/− Ovarian Cancer Cells 2019 ·Molecular Cancer Therapeutics ·Lu Liu, Shurui Cai, Chunhua Han, Ananya Banerjee, Dayong Wu, (unknown), (unknown), Junran Zhang, Xiaoli Zhang, Eric McLaughlin, Ming Yin, Floor Backes, Arnab Chakravarti, Yanfang Zheng, Qi‐En Wang	51
7	Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study 2017 ·BMC Cancer ·Ming Yin, Wenge Wang, Joseph J. Drabick, (unknown)	62
8	Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis breakdown → 2016 ·The Oncologist ·Ming Yin, Monika Joshi, Richard P. Meijer, Michael Glantz, Sheldon L. Holder, Harold A. Harvey, Matthew Kaag, Elisabeth E. Fransen van de Putte, Simon Horenblas, Joseph J. Drabick	314
9	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study 2014 ·The Lancet Oncology ·Antoni Ribas, René González, Anna C. Pavlick, Omid Hamid, Thomas F. Gajewski, Adil Daud, Lawrence E. Flaherty, Theodore F. Logan, Bartosz Chmielowski, Karl D. Lewis, Damien Kee, Peter D. Boasberg, Ming Yin, Iris T. Chan, Luna Musib, Nicholas W. Choong, Igor Puzanov, Grant A. McArthur	201
10	Isolated Hemolytic Anemia: An Unusual Manifestation of Occult Malignancy 2014 ·Hematology Reports ·Matthew Butler, Ming Yin, (unknown)	2
11	Amylase α-1A (AMY1A) 2013 ·The American Journal of Surgical Pathology ·(unknown), Somak Roy, (unknown), Marie Acquafondata, Ming Yin, William A. LaFramboise, Sheldon Bastacky, Liron Pantanowitz, Rajiv Dhir, Anil V. Parwani	14
12	Incorporating Single-nucleotide Polymorphisms Into the Lyman Model to Improve Prediction of Radiation Pneumonitis 2012 ·International Journal of Radiation OncologyBiologyPhysics ·Susan L. Tucker, Minghuan Li, Ting Xu, Daniel R. Gomez, Xianglin Yuan, Jinming Yu, Zhensheng Liu, Ming Yin, Xiaoxiang Guan, Li‐E Wang, Qingyi Wei, Radhe Mohan, Yevgeniy Vinogradskiy, Mary K. Martel, Zhongxing Liao	56
13	TERT-CLPTM1L Polymorphism rs401681 Contributes to Cancers Risk: Evidence from a Meta-Analysis Based on 29 Publications 2012 ·PLoS ONE ·Jieyun Yin, Yangkai Li, Ming Yin, (unknown), Li Liu, Qin Qin, Xiaorong Li, Lü Long, Shaofa Nie, Sheng Wei	22
14	Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy 2011 ·Cancer ·Ming Yin, Zhongxing Liao, Zhensheng Liu, Li‐E Wang, Michael S. O’Reilly, Daniel R. Gomez, Minghuan Li, Ritsuko Komaki, Qingyi Wei	68
15	Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma 2010 ·European Journal of Cancer ·Li‐E Wang, (unknown), Ming Yin, Jeffrey E. Gershenwald, Víctor G. Prieto, Jeffrey E. Lee, Madeleine Duvic, Elizabeth A. Grimm, Qingyi Wei	10
16	CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies 2010 ·Carcinogenesis ·Ming Yin, (unknown), Sheng Wei, Qingyi Wei	34
17	Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy 2010 ·BMC Cancer ·Xiaoxiang Guan, Ming Yin, Qingyi Wei, Hui Zhao, Zhensheng Liu, Li E. Wang, Xianglin Yuan, Michael S. O’Reilly, Ritsuko Komaki, Zhongxing Liao	26
18	Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. 2009 ·PubMed ·Ming Yin, Xiaoxiang Guan, Zhongxing Liao, Qingyi Wei	25
19	Endotoxin Exposure Is a Risk Factor for Asthma 2005 ·American Journal of Respiratory and Critical Care Medicine ·Peter S. Thorne, Katarina Kulhánková, Ming Yin, Richard D. Cohn, Samuel J. Arbes, Darryl C. Zeldin	272
20	Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. 1997 ·Journal of Clinical Oncology ·Y M Rustum, A. Harstrick, Shu Cao, U. Vanhoefer, Ming Yin, H. Wilke, S. Seeber	162

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact